Adial Pharmaceuticals, Inc

(NASDAQ:ADIL)

Latest On Adial Pharmaceuticals, Inc (ADIL):

Date/Time Type Description Signal Details
2023-03-31 16:31 ESTNewsAdial Pharmaceuticals reports FY resultsN/A
2023-03-07 15:32 ESTNewsAdial soars 63% after regulatory update on lead assetN/A
2023-02-24 14:01 ESTNewsAdial Pharmaceuticals prices $0.75M in stock offeringN/A
2022-11-14 21:47 ESTNewsAdial Pharmaceuticals GAAP EPS of -$0.12 beats by $0.06N/A
2022-08-22 16:47 ESTNewsAdial Clinical Trial: A Fluff Or A Win?N/A
2022-08-22 16:45 ESTNewsAdial Pharmaceuticals names new executive chiefN/A
2022-08-17 13:31 ESTNewsAdial gets cut at Maxim on need for capital to map path for alcohol disorder drugN/A
2022-08-16 20:31 ESTNewsAdial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01N/A
2022-07-20 18:02 ESTNewsAdial stock slumps 25% as AD04 fails to best placebo in very heavy drinkers in trialN/A
2022-06-15 04:31 ESTNewsAdial gets US patent linked to AD04, diagnostic test for alcohol/opioid use disorderN/A
2022-05-17 02:46 ESTNewsAdial Pharmaceuticals GAAP EPS of -$0.13 beats by $0.04N/A
2022-05-17 02:46 ESTNewsAdial Pharmaceuticals reports Q1 resultsN/A
2022-02-11 15:46 ESTNewsAdial Pharmaceuticals announces $10M registered direct offeringN/A
2022-01-24 16:17 ESTNewsAdial Pharma secures new U.S. patent for AD04 for treatment of opioid use disorderN/A
2021-11-11 00:18 ESTNewsWarning: ADIL is at high risk of performing badlyN/A
2021-10-22 01:18 ESTNewsPurnovate picks PNV-5030 as lead compound for pain treatment programN/A
2021-09-28 11:00 ESTNewsAdial Pharmaceuticals inks research collaboration agreement with University of VirginiaN/A
2021-08-20 19:02 ESTNewsAdial Pharma reaches enrollment goal in late-stage trial for alcohol use disorderN/A
2021-08-10 19:33 ESTNewsAdial Pharmaceuticals awarded U.S. and international patents for AD04N/A
2021-07-20 17:44 ESTNewsRevisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical CatalystN/A
2021-07-20 17:44 ESTNewsAdial Pharmaceuticals shares jump on plans to enter the genetic testing marketN/A
2021-07-20 17:44 ESTNewsIdera Pharmaceuticals, Beyond Air leads healthcare gainers; Mereo BioPharma, Portage Biotech among major losersN/A
2021-07-20 17:43 ESTNewsAdial Pharma drops 3% as FDA rejects Fast Track request for AD04N/A
2021-07-20 17:41 ESTNewsAdial Pharmaceuticals rallies on inclusion in Russell Microcap IndexN/A
2021-07-20 17:33 ESTNewsAdial provides enrollment update for late-stage AD04 Alcohol Use Disorder studyN/A
2021-07-20 17:31 ESTNewsAdial enters $5M private placementN/A
2021-03-15 10:00 ESTNewsAdial launches $2.1M management-led private placementN/A
2021-02-26 14:16 ESTNewsAdial receives $1.43M in proceeds from warrants exercisingN/A
2021-02-25 18:34 ESTNewsAdial achieves 50% enrollment in late-stage ONWARD AD04 trialN/A
2021-01-12 04:32 ESTNewsAdial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidateN/A
2020-12-13 03:02 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 01:02 ESTNewsAdial Pharmaceuticals acquires PurnovateN/A
2020-11-25 16:33 ESTNewsAdial Pharmaceuticals inks stock purchase agreement with Keystone CapitalN/A
2020-11-25 11:04 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 11:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-16 07:02 ESTEarnings EstimateAn EPS average of -$0.15 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-01 16:50 ESTFinancialsCompany financials have been released.Neutral
2020-10-22 15:04 ESTNewsAvalon GloboCare and Adial Pharma rallies on strategic collaborationN/A
2020-10-22 15:03 ESTNewsTodos Medical inks distribution agreement with Adial PharmaN/A
2020-10-21 14:03 ESTNewsFDA lifts clinical hold on Adial Pharma IND for alcohol use disorder candidateN/A
2020-10-18 12:31 ESTNewsAdial Pharmaceuticals: Opportunity Knocks For Micro Cap Targeting Multi-Billion Alcohol Use Disorder MarketN/A
2020-10-01 03:32 ESTNewsAdial Pharmaceuticals receives COVID-19 antibody rapid test devices orderN/A
2020-09-29 21:02 ESTNewsAdial Pharma up 54% on FDA emergency use nod for fingerstick COVID-19 blood testN/A
2020-09-26 04:02 ESTFinancialsCompany financials have been released.Neutral
2020-09-25 10:46 ESTNewsAdial Pharma +10% after filing for AD04's FDA expedited reviewN/A
2020-09-24 16:03 ESTFinancialsCompany financials have been released.Neutral
2020-09-22 21:03 ESTNewsAdial commence sale of COVID-19 test kits in the U.S.N/A
2020-08-24 17:15 ESTInsider TradeBankole A. Johnson has directly disposed of 350,000 shares and currently holds 1,055 shares.Sell
2020-08-16 08:02 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 04:01 ESTEarnings EstimateAn EPS average of -$0.58 is estimated for the 2021 year.Sell

About Adial Pharmaceuticals, Inc (ADIL):

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.

ADIL Quotes by TradingView

See Advanced Chart

General

  • Name Adial Pharmaceuticals, Inc
  • Symbol ADIL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 3
  • Fiscal Year EndDecember
  • IPO Date2018-07-30
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.adialpharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 6
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.19
  • Return on Assets -67%
  • Return on Equity -120%
  • Earnings Per Share -$1.86
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 39.6 million
  • EBITDA -9313408
  • Analyst Target Price $5
  • Book Value Per Share $0.50
View More

Share Statistics

  • Shares Outstanding 15.23 million
  • Shares Float 11.79 million
  • % Held by Insiders 1753%
  • % Held by Institutions 9.82%
  • Shares Short 505703
  • Shares Short Prior Month 469814
  • Short Ratio 0.47
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 0.69
  • 52 Week High $3.3
  • 52 Week Low $1.01
  • 50 Day Moving Average 2.6
  • 200 Day Moving Average 2.01
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Adial Pharmaceuticals, Inc (ADIL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Adial Pharmaceuticals, Inc (ADIL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.24-$0.18-33.33%
2020-06-302020-08-13$N/A-$0.16-$0.1811.11%
2020-03-312020-05-14$N/A-$0.22
2019-12-312020-03-20$N/A-$0.19-$0.190%
2019-09-302019-11-14$N/A-$0.17-$0.2941.38%
2019-06-302019-08-13$N/A-$0.21-$0.238.7%
2019-03-312019-05-13$N/A-$0.33-$0.17-94.12%
2018-12-312019-02-19$N/A-$0.19-$0.18-5.56%
2018-09-302018-11-14$N/A-$1.48-$0.26-469.23%
2018-06-302018-07-30$N/A-$0.27

Adial Pharmaceuticals, Inc (ADIL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 1.06 million 1.2 million 864280
Income Before Tax N/A N/A -2.28 million -2.06 million -1.72 million
Selling General Administrative N/A N/A 1.24 million 886969 881462
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -2.3 million -2.09 million -1.75 million
Operating Income N/A N/A -2.3 million -2.09 million -1.75 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 32394 29859
Net Income From Continuing Operations N/A N/A -2.28 million -2.06 million -1.72 million
Net Income Applicable to Common Shares -3.34 million -1.81 million N/A -2.06 million -1.72 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities -194975 245993 N/A -428439 150393
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 109 178
Change to Operating Activities 644134 184351 N/A 265063 -544040
Change in Cash N/A N/A -1.83 million -1.75 million -1.72 million
Total Cash from Operating Activities -2.21 million -985173 -1.83 million -1.75 million -1.72 million
Depreciation N/A N/A 141 141 141
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 677992 395452 N/A 468985 384869
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 389829 539051 776946
Total Stockholder Equity N/A N/A 5.55 million 7.14 million 8.73 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A 5.94 million 7.68 million 9.51 million
Common Stock 14218 13449 N/A 10368 10295
Other Current Assets 214409 N/A N/A 536916 460055
Retained Earnings -28.05 million -24.71 million -22.9 million -20.63 million -18.57 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash N/A N/A 4.95 million 6.78 million 8.53 million
Total Current Liabilities 1.09 million N/A 389829 539051 776946
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment N/A N/A N/A N/A N/A
Total Current Assets 8.17 million N/A 5.94 million 7.67 million 9.5 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 7.08 million 8.79 million N/A 7.13 million 8.72 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 247400 N/A 196382 190204 776946

Adial Pharmaceuticals, Inc (ADIL) Chart:

Adial Pharmaceuticals, Inc (ADIL) News:

Below you will find a list of latest news for Adial Pharmaceuticals, Inc (ADIL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Adial Pharmaceuticals, Inc (ADIL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ADIL Trades:

Date Shares Price
Jun 13, 2022 2:52 PM EST100$1.25
Jun 13, 2022 5:26 PM EST100$1.335
Jun 13, 2022 5:43 PM EST20$1.31
Jun 13, 2022 5:43 PM EST3$1.31
Jun 13, 2022 6:20 PM EST100$1.33

Adial Pharmaceuticals, Inc (ADIL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-02S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390020016605/0001213900-20-016605-index.htm
2019-02-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1513525/000000000019001637/0000000000-19-001637-index.htm
2019-03-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1513525/000000000019006089/0000000000-19-006089-index.htm
2020-04-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1513525/000000000020003603/0000000000-20-003603-index.htm
2020-07-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1513525/000000000020006125/0000000000-20-006125-index.htm
2019-03-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513525/000090266419001327/0000902664-19-001327-index.htm
2020-01-21SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513525/000090266420000306/0000902664-20-000306-index.htm
2020-06-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513525/000091957420004217/0000919574-20-004217-index.htm
2018-07-10S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390018008954/0001213900-18-008954-index.htm
2018-07-10FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018008967/0001213900-18-008967-index.htm
2018-07-238-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1513525/000121390018009518/0001213900-18-009518-index.htm
2018-07-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009574/0001213900-18-009574-index.htm
2018-07-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009576/0001213900-18-009576-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009709/0001213900-18-009709-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009711/0001213900-18-009711-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009713/0001213900-18-009713-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009715/0001213900-18-009715-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009717/0001213900-18-009717-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009719/0001213900-18-009719-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009722/0001213900-18-009722-index.htm
2018-07-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018009725/0001213900-18-009725-index.htm
2018-07-30424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1513525/000121390018009822/0001213900-18-009822-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010083/0001213900-18-010083-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010085/0001213900-18-010085-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010087/0001213900-18-010087-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010089/0001213900-18-010089-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010092/0001213900-18-010092-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010095/0001213900-18-010095-index.htm
2018-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018010099/0001213900-18-010099-index.htm
2018-08-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018011309/0001213900-18-011309-index.htm
2018-09-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390018012298/0001213900-18-012298-index.htm
2018-09-10424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1513525/000121390018012305/0001213900-18-012305-index.htm
2018-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390018012880/0001213900-18-012880-index.htm
2018-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015546/0001213900-18-015546-index.htm
2018-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015548/0001213900-18-015548-index.htm
2018-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015554/0001213900-18-015554-index.htm
2018-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015557/0001213900-18-015557-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390018015559/0001213900-18-015559-index.htm
2018-11-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015600/0001213900-18-015600-index.htm
2018-11-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015602/0001213900-18-015602-index.htm
2018-11-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015606/0001213900-18-015606-index.htm
2018-11-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1513525/000121390018015610/0001213900-18-015610-index.htm
2018-11-14424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1513525/000121390018015655/0001213900-18-015655-index.htm
2018-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390018017537/0001213900-18-017537-index.htm
2018-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390018017831/0001213900-18-017831-index.htm
2019-01-07DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1513525/000121390019000233/0001213900-19-000233-index.htm
2019-01-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019001194/0001213900-19-001194-index.htm
2019-01-258-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019001241/0001213900-19-001241-index.htm
2019-02-12S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390019002177/0001213900-19-002177-index.htm
2019-02-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390019002196/0001213900-19-002196-index.htm
2019-02-13FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019002279/0001213900-19-002279-index.htm
2019-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390019002312/0001213900-19-002312-index.htm
2019-02-1910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1513525/000121390019002769/0001213900-19-002769-index.htm
2019-02-19S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390019002771/0001213900-19-002771-index.htm
2019-02-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390019002773/0001213900-19-002773-index.htm
2019-02-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390019002775/0001213900-19-002775-index.htm
2019-02-22424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1513525/000121390019003016/0001213900-19-003016-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019003128/0001213900-19-003128-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019004001/0001213900-19-004001-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019004003/0001213900-19-004003-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019004125/0001213900-19-004125-index.htm
2019-03-22S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390019004699/0001213900-19-004699-index.htm
2019-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019004830/0001213900-19-004830-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019004831/0001213900-19-004831-index.htm
2019-03-29S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390019005164/0001213900-19-005164-index.htm
2019-03-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390019005166/0001213900-19-005166-index.htm
2019-03-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1513525/000121390019005178/0001213900-19-005178-index.htm
2019-04-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1513525/000121390019005522/0001213900-19-005522-index.htm
2019-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019005524/0001213900-19-005524-index.htm
2019-04-02424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1513525/000121390019005565/0001213900-19-005565-index.htm
2019-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019007376/0001213900-19-007376-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390019008448/0001213900-19-008448-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019011052/0001213900-19-011052-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019012204/0001213900-19-012204-index.htm
2019-07-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019012205/0001213900-19-012205-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390019015413/0001213900-19-015413-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019016383/0001213900-19-016383-index.htm
2019-09-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019018002/0001213900-19-018002-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019019766/0001213900-19-019766-index.htm
2019-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019019784/0001213900-19-019784-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390019023298/0001213900-19-023298-index.htm
2019-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390019026186/0001213900-19-026186-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019026188/0001213900-19-026188-index.htm
2019-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390019027287/0001213900-19-027287-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020002805/0001213900-20-002805-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005537/0001213900-20-005537-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005539/0001213900-20-005539-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005541/0001213900-20-005541-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005543/0001213900-20-005543-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005545/0001213900-20-005545-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005547/0001213900-20-005547-index.htm
2020-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005549/0001213900-20-005549-index.htm
2020-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020005557/0001213900-20-005557-index.htm
2020-03-2010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1513525/000121390020007020/0001213900-20-007020-index.htm
2020-03-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020007568/0001213900-20-007568-index.htm
2020-03-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020007845/0001213900-20-007845-index.htm
2020-04-22S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390020009839/0001213900-20-009839-index.htm
2020-04-22POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1513525/000121390020009842/0001213900-20-009842-index.htm
2020-04-22POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1513525/000121390020009843/0001213900-20-009843-index.htm
2020-04-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390020010229/0001213900-20-010229-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390020012328/0001213900-20-012328-index.htm
2020-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020013069/0001213900-20-013069-index.htm
2020-05-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020013162/0001213900-20-013162-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020013163/0001213900-20-013163-index.htm
2020-05-22424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1513525/000121390020013332/0001213900-20-013332-index.htm
2020-05-22424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1513525/000121390020013336/0001213900-20-013336-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020013504/0001213900-20-013504-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020014346/0001213900-20-014346-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020014594/0001213900-20-014594-index.htm
2020-06-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1513525/000121390020014598/0001213900-20-014598-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020014671/0001213900-20-014671-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020014731/0001213900-20-014731-index.htm
2020-06-17DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020015161/0001213900-20-015161-index.htm
2020-06-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020015264/0001213900-20-015264-index.htm
2020-07-02S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513525/000121390020016605/0001213900-20-016605-index.htm
2020-07-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513525/000121390020016969/0001213900-20-016969-index.htm
2020-07-13424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1513525/000121390020017356/0001213900-20-017356-index.htm
2020-07-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020018019/0001213900-20-018019-index.htm
2020-07-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020018048/0001213900-20-018048-index.htm
2020-07-31DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1513525/000121390020019495/0001213900-20-019495-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020019496/0001213900-20-019496-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020020540/0001213900-20-020540-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513525/000121390020021918/0001213900-20-021918-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020023494/0001213900-20-023494-index.htm
2020-08-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020023564/0001213900-20-023564-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020024915/0001213900-20-024915-index.htm
2020-09-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020026280/0001213900-20-026280-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020027253/0001213900-20-027253-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020027649/0001213900-20-027649-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020027739/0001213900-20-027739-index.htm
2020-09-25DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1513525/000121390020028472/0001213900-20-028472-index.htm
2020-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020028582/0001213900-20-028582-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020029096/0001213900-20-029096-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020029425/0001213900-20-029425-index.htm
2020-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020032495/0001213900-20-032495-index.htm
2020-11-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513525/000121390020034675/0001213900-20-034675-index.htm
2018-07-27CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1513525/000135445718000288/0001354457-18-000288-index.htm
2018-07-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999518001892/9999999995-18-001892-index.htm
2018-07-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999518002166/9999999995-18-002166-index.htm
2019-02-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999519000305/9999999995-19-000305-index.htm
2019-04-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999519000565/9999999995-19-000565-index.htm
2020-04-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999520000864/9999999995-20-000864-index.htm
2020-04-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999520000871/9999999995-20-000871-index.htm
2020-04-30EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999520000938/9999999995-20-000938-index.htm
2020-07-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513525/999999999520001774/9999999995-20-001774-index.htm

Adial Pharmaceuticals, Inc (ADIL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adial Pharmaceuticals, Inc (ADIL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1753%
Institutional Ownership: 982%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-31James W. Jr. NewmanDirectorBuy10,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010089/0001213900-18-010089-index.htm
2020-08-20Bankole A. JohnsonChief Medical OfficerSell350,000.001.21423,500.001,055.00https://www.sec.gov/Archives/edgar/data/1513525/000121390020023494/0001213900-20-023494-index.htm
2020-03-03Joseph TruluckChief Financial OfficerBuy27,084.00107,639.00https://www.sec.gov/Archives/edgar/data/1513525/000121390020005543/0001213900-20-005543-index.htm
2018-07-31Robertson H. GillilandDirectorBuy14,000.00109,424.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010083/0001213900-18-010083-index.htm
2020-03-27James W. Jr. NewmanDirectorBuy10,000.001.3413,400.0013,288.00https://www.sec.gov/Archives/edgar/data/1513525/000121390020007845/0001213900-20-007845-index.htm
2018-07-31Bankole A. JohnsonDirectorBuy1,400.001,400.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010087/0001213900-18-010087-index.htm
2020-03-27James W. Jr. NewmanDirectorBuy4,644.001.356,269.4014,644.00https://www.sec.gov/Archives/edgar/data/1513525/000121390020007845/0001213900-20-007845-index.htm
2020-03-27James W. Jr. NewmanDirectorBuy5,000.001.427,100.0015,000.00https://www.sec.gov/Archives/edgar/data/1513525/000121390020007845/0001213900-20-007845-index.htm
2018-07-31James W. Jr. NewmanDirectorBuy10,000.00150,419.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010089/0001213900-18-010089-index.htm
2018-07-31Bankole A. JohnsonDirectorBuy40,382.00313,750.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010087/0001213900-18-010087-index.htm
2019-03-28Bankole A. JohnsonChief Medical OfficerBuy40,000.003.15125,808.00314,768.00https://www.sec.gov/Archives/edgar/data/1513525/000121390019005524/0001213900-19-005524-index.htm
2018-07-31Kevin SchuylerDirectorBuy90,000.00343,390.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010092/0001213900-18-010092-index.htm
2019-03-29Bankole A. JohnsonChief Medical OfficerBuy30,000.003.47104,154.00344,768.00https://www.sec.gov/Archives/edgar/data/1513525/000121390019005524/0001213900-19-005524-index.htm
2019-03-29Bankole A. JohnsonChief Medical OfficerBuy2,500.003.478,669.00347,268.00https://www.sec.gov/Archives/edgar/data/1513525/000121390019005524/0001213900-19-005524-index.htm
2019-03-29Bankole A. JohnsonChief Medical OfficerBuy600.003.301,978.02347,868.00https://www.sec.gov/Archives/edgar/data/1513525/000121390019005524/0001213900-19-005524-index.htm
2019-10-02Bankole A. JohnsonChief Medical OfficerBuy3,187.00351,055.00https://www.sec.gov/Archives/edgar/data/1513525/000121390019019766/0001213900-19-019766-index.htm
2018-07-31William B. III StilleyChief Executive OfficerBuy80,000.00504,000.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010095/0001213900-18-010095-index.htm
2020-03-03William B. III StilleyChief Executive OfficerBuy54,167.00690,937.00https://www.sec.gov/Archives/edgar/data/1513525/000121390020005545/0001213900-20-005545-index.htm
2019-12-12Bankole A. JohnsonChief Medical OfficerSell150,000.001.00150,000.00698,336.00https://www.sec.gov/Archives/edgar/data/1513525/000121390019026186/0001213900-19-026186-index.htm
2018-07-31Tony GoodmanDirectorBuy7,000.008,755.00https://www.sec.gov/Archives/edgar/data/1513525/000121390018010085/0001213900-18-010085-index.htm